Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | VDR | P11473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28446183 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CA12CA1CA9KDM4E | |
| SCHEMBL30918124 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CA12CA1CA9KDM4E | |
| SCHEMBL1056101 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CA12CA1CA9KDM4E | |
| SCHEMBL244712 | 0.98 | CA12 (0.46) | ALDH1A1CA12CA1CA9KDM4E | |
| SCHEMBL28536775 | 0.94 | ALDH1A1 (0.44) | ALDH1A1CA12CA1CA9KDM4E | |
| SCHEMBL881292 | 0.93 | ALDH1A1 (0.53) | ALDH1A1CA12CA1CA9KDM4E | |
| SCHEMBL4379133 | 0.93 | ALDH1A1 (0.53) | ALDH1A1CA12CA1CA9KDM4E | |
| SCHEMBL18613994 | 0.93 | ALDH1A1 (0.53) | ALDH1A1CA12CA1CA9KDM4E | |
| SCHEMBL18644929 | 0.93 | ALDH1A1 (0.53) | ALDH1A1CA12CA1CA9KDM4E | |
| SCHEMBL922407 | 0.93 | ALDH1A1 (0.53) | ALDH1A1CA12CA1CA9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584251-A1 | NEW CONTRAST AGENTS FOR USE IN DIAGNOSTIC IMAGING | Bayer Aktiengesellschaft (DE) | 2025-07-16 | — | — | EP | disclosed |
| US-RE50082-E1 | (5,6-dihydro)pyrimido[4,5-e]indolizines | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2024-08-20 | — | — | US | disclosed |
| US-12054784-B2 | Prognostic biomarkers for TTK inhibitor chemotherapy | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2024-08-06 | — | — | US | disclosed |
| WO-2024052549-A1 | NEW CONTRAST AGENTS FOR USE IN DIAGNOSTIC IMAGING | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024052549-A1 | NEW CONTRAST AGENTS FOR USE IN DIAGNOSTIC IMAGING | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-14 | — | — | WO | disclosed |
| EP-4335840-A1 | NEW CONTRAST AGENTS FOR USE IN DIAGNOSTIC IMAGING | Bayer Aktiengesellschaft (DE) | 2024-03-13 | — | — | EP | disclosed |
| EP-3283642-B1 | PROGNOSTIC BIOMARKERS FOR TTK INHIBITOR CHEMOTHERAPY | NETHERLANDS TRANSLATIONAL RES CENTER HOLDING B V (NL) | 2023-10-11 | — | — | EP | disclosed |
| US-20230098686-A1 | NERVE SPECIFIC FLUOROPHORE FORMULATIONS FOR DIRECT AND SYSTEMIC ADMINISTRATION | UNIV OREGON HEALTH & SCIENCE (US) | 2023-03-30 | — | — | US | disclosed |
| US-20230098438-A1 | OXAZINE-BASED WATER-SOLUBLE FLUOROPHORE COMPOUNDS FOR IN VIVO NERVE IMAGING | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2023-03-30 | — | — | US | disclosed |
| EP-3519386-B1 | NOVEL PI-CONJUGATED MATERIALS, METHODS FOR PREPARING SAME AND USES THEREOF AS SEMICONDUCTORS | DEGBIA MARTIAL (FR) | 2023-03-29 | — | — | EP | disclosed |
| EP-0349748-A1 | Substituted N-aryl-nitrogen containing heterocycles | BAYER AG (DE) | 1990-01-10 | — | — | EP | disclosed |
| US-4655783-A | COPPER COMPLEXES | CIBA-GEIGY CORPORATION (US) | 1987-04-07 | — | — | US | disclosed |
| US-4388104-A | 3-Phenylmethoxytetrahydropyran herbicides | SHELL OIL COMPANY (US) | 1983-06-14 | — | — | US | disclosed |
| US-4371533-A | ANTITUMOR, ANTIPROTOZOA AND ANTIFUNGAL AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1983-02-01 | — | — | US | disclosed |
| EP-0049528-A1 | 4,5-Deoxymaytansinoids, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1982-04-14 | — | — | EP | disclosed |
| US-4309428-A | Maytansinoids | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1982-01-05 | — | — | US | disclosed |
| EP-0025496-A1 | Maytansinoids, their production and therapeutic compositions containing them | Takeda Chemical Industries, Ltd. (JP) | 1981-03-25 | — | — | EP | disclosed |
| US-4111937-A | IODINATED ANILIC ACIDS | STERLING DRUG INC. (US) | 1978-09-05 | — | — | US | disclosed |
| US-4031088-A | Iodinated anilic acids | STERLING DRUG INC. (US) | 1977-06-21 | — | — | US | disclosed |
| US-4018832-A | Novel complexing agents derived from cyclotriveratrylene | EASTMAN KODAK COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230098438-A1 | OXAZINE-BASED WATER-SOLUBLE FLUOROPHORE COMPOUNDS FOR IN VIVO NERVE IMAGING | GAP43, NTRK1, MAG | ALDH1A1 861/4885CA12 2344/4885CA1 1882/4885 |
| US-20230098686-A1 | NERVE SPECIFIC FLUOROPHORE FORMULATIONS FOR DIRECT AND SYSTEMIC ADMINISTRATION | PFAS, NPFFR2, NPFFR1 | ALDH1A1 556/4885CA12 2687/4885CA1 3277/4885 |
| US-12054784-B2 | Prognostic biomarkers for TTK inhibitor chemotherapy | TTBK1, CTNNB1, TTK | ALDH1A1 2286/4885CA12 4232/4885CA1 4584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.